Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Raza Mirza, Mansoor; M. Chase, Dana; M. Slomovitz, Brian; dePont Christensen, René; Novàk, Zoltán; Black, Destin; Gilbert, Lucy; Sharma, Sudarshan; Valabrega, Giorgio; M. Landrum, Lisa; Hanker, Lars; Stuckey, Ashley; Boere, Ingrid; A. Gold, Michael; Auranen, Annika; Pothuri, Bhavana; Cibula, David; K. McCourt, Carolyn; Raspagliesi, Francesco; S. Shahin, Mark; Gill, Sarah; J. Monk, Bradley; Buscema, Joseph; J. Herzog, Thomas; J. Copeland, Larry; Tian, Min; He, Zangdong; Stevens, Shadi; Zografos, Eleftherios; L. Coleman, Robert; A. Powell, Matthew

doi:10.1056/nejmoa2216334

Public

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Published in New England Journal of Medicine • Mar 27, 2023

Authors:

Mansoor Raza Mirza

Dana M. Chase

Brian M. Slomovitz

Abstract

BACKGROUND: Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer. METHODS: We conducted a phase 3, global, double-blind, randomized, place...

Subject

Endometrial cancer

Primary (astronomy)

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!